Details

Autor(en) / Beteiligte

• Vogelzang, Erik H
• Loeff, Floris C
• Derksen, Ninotska I L
• Kruithof, Simone
• Ooijevaar-de Heer, Pleuni
• van Mierlo, Gerard
• Linty, Federica
• Mok, Juk Yee
• van Esch, Wim
• de Bruin, Sanne
• Vlaar, Alexander P J
• Seppen, Bart
• Leeuw, Maureen
• van Oudheusden, Anne J G
• Buiting, Anton G M
• Jim, Kin Ki
• Vrielink, Hans
• Swaneveld, Francis
• Vidarsson, Gestur
• van der Schoot, C Ellen
• Wever, Peter C
• Li, Wentao
• van Kuppeveld, Frank
• Murk, Jean-Luc
• Bosch, Berend Jan
• Wolbink, Gerrit-Jan
• Rispens, Theo

Titel

Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19

Ist Teil von

• The Journal of immunology (1950), 2020-12, Vol.205 (12), p.3491-3499

Ort / Verlag

United States

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients ( = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors ( = 182), PCR-confirmed hospital care workers ( = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 ( = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies.